Sellers E M, Holloway M R
Clin Pharmacokinet. 1978 Nov-Dec;3(6):440-52. doi: 10.2165/00003088-197803060-00002.
Acute and chronic ethanol ingestion can alter both the pharmacodynamics and pharmacokinetics of other drugs. For psychotherapeutic drugs, modification of drug action by alcohol is much more important than kinetic interaction, such as ethanol induced drug metabolism. In contrast, the importance of the effects of alcohol on the kinetics of other classes of drug is incomplete. The probability and mechanism of alcohol kinetic interactions with other drugs can nevertheless be anticipated, in part, on the basis of the extent of binding of the drug to plasma proteins, the capacity of the liver for extracting the drug from blood passing through the liver and the true distribution space of the drug. Highly bound drugs with low intrinsic hepatic clearance are among the most commonly reported to have their kinetics altered by ethanol (e.g. benzodiazepines, phenytoin, tolbutamide and warfarin). Less highly bound drugs are less consistently affected (e.g. meprobamate, glutethimide, pentobarbitone and phenobarbitone). Acute administration of ethanol to laboratory animals or incubation of microsomal preparations with ethanol inhibits the mixed function oxidase activity. In the human, the elimination half-life of meprobamate, pentobarbitone and tolbutamide is increased by acute ethanol administration. Chronic administration of ethanol to rats and humans causes proliferation of the smooth endoplasmic reticulum, increase in microsomal protein content and cytochrome P450 and results in an augmentation in drug metabolising ability of the microsomes in vitro. Even though the plasma half-life of some drugs is decreased by chronic ethanol ingestion, the clinical determination of the mechanism is incomplete because few studies have measured drug metabolite levels. In addition, alcohol effects on drug distribution have not been studied very extensively. The effects of chronic alcohol ingestion on drugs with low and high hepatic extraction, high and low binding, important tissue localisation and microsomal and non-microsomal metabolism will be quite different. Systematic studies of the mechanism of alcohol kinetic interactions are needed. Such kinetic studies should be combined with pharmacodynamic measures in order to establish the clinical importance of changes in drug kinetics.
急性和慢性摄入乙醇均可改变其他药物的药效学和药代动力学。对于精神治疗药物而言,酒精对药物作用的改变比动力学相互作用(如乙醇诱导的药物代谢)更为重要。相比之下,酒精对其他类别药物动力学影响的重要性尚不完全清楚。不过,酒精与其他药物动力学相互作用的可能性和机制,部分可根据药物与血浆蛋白的结合程度、肝脏从流经肝脏的血液中提取药物的能力以及药物的真实分布空间来预测。与血浆蛋白高度结合且肝脏内在清除率低的药物是最常被报道其动力学受乙醇影响的药物(如苯二氮䓬类、苯妥英、甲苯磺丁脲和华法林)。与血浆蛋白结合程度较低的药物受影响的情况则不太一致(如甲丙氨酯、格鲁米特、戊巴比妥和苯巴比妥)。对实验动物急性给予乙醇或使微粒体制剂与乙醇孵育会抑制混合功能氧化酶活性。在人体中,急性给予乙醇会使甲丙氨酯、戊巴比妥和甲苯磺丁脲的消除半衰期延长。对大鼠和人体长期给予乙醇会导致滑面内质网增生、微粒体蛋白含量增加以及细胞色素P450增加,并使微粒体在体外的药物代谢能力增强。尽管长期摄入乙醇会使某些药物的血浆半衰期缩短,但由于很少有研究测量药物代谢物水平,因此对其机制的临床判定并不完整。此外,酒精对药物分布的影响尚未得到广泛研究。长期摄入酒精对具有低和高肝脏提取率、高和低结合率、重要组织定位以及微粒体和非微粒体代谢的药物的影响会有很大不同。需要对酒精动力学相互作用的机制进行系统研究。此类动力学研究应与药效学测量相结合,以确定药物动力学变化的临床重要性。